Volume 16, Number 1—January 2010
Acute Encephalopathy Associated with Influenza A Infection in Adults
Highlight and copy the desired format.
|EID||Lee N, Wong CK, Chan P, Lindegardh N, White NJ, Hayden FG, et al. Acute Encephalopathy Associated with Influenza A Infection in Adults. Emerg Infect Dis. 2010;16(1):139-142. https://dx.doi.org/10.3201/eid1601.090077|
|AMA||Lee N, Wong CK, Chan P, et al. Acute Encephalopathy Associated with Influenza A Infection in Adults. Emerging Infectious Diseases. 2010;16(1):139-142. doi:10.3201/eid1601.090077.|
|APA||Lee, N., Wong, C. K., Chan, P., Lindegardh, N., White, N. J., Hayden, F. G....Hui, D. S. (2010). Acute Encephalopathy Associated with Influenza A Infection in Adults. Emerging Infectious Diseases, 16(1), 139-142. https://dx.doi.org/10.3201/eid1601.090077.|
We report acute encephalopathy associated with influenza A infection in 3 adults. We detected high cerebrospinal fluid (CSF) and plasma concentrations of CXCL8/IL-8 and CCL2/MCP-1 (CSF/plasma ratios >3), and interleukin-6, CXCL10/IP-10, but no evidence of viral neuroinvasion. Patients recovered without sequelae. Hyperactivated cytokine response may play a role in pathogenesis.
Influenza-associated acute encephalopathy has been described in children, and results in a high frequency of neurologic sequelae and death. Altered consciousness, disorientation, and seizures occur within a few days after the onset of fever and respiratory symptoms (1–3). In some patients, symptoms are transient but in others rapid progression to necrotizing encephalitis, deep coma, and death may occur (1–3). Cases in adults are infrequently reported and remain poorly characterized, although the more complex clinical scenarios in adults may have hindered case recognition (1,4–6). The pathogenesis is unclear, but a hyperactivated cytokine response, rather than viral invasion, is believed responsible in most childhood cases (1–5). We describe 3 cases of acute encephalopathy associated with influenza A infection in adults. The clinical, virologic, immunologic findings (cytokines in plasma and cerebrospinal fluid [CSF]), and CSF penetration of oseltamivir for these cases are reported.
At Prince of Wales Hospital, Hong Kong (7), from January 2007 through August 2008, influenza infection was diagnosed for >460 hospitalized adult patients for whom acute febrile respiratory illnesses had been diagnosed. Nasopharyngeal aspiration and immunofluorescence assays (IFA) were used for rapid diagnosis of influenza A and B infection, confirmed by virus isolation. Thirteen (2.8%) patients had signs of confusion or altered consciousness, together with fever and respiratory symptoms (mean ± SD age 77.7 ± 8.8 years). We studied 3 patients from whom CSF was obtained for analysis, and who fulfilled the definition of influenza-associated acute encephalopathy (altered mental status >24 hours within 5 days of influenza onset and without alternative explanation) (1,2,4–6).
Nasopharyngeal aspirates were subjected to IFA, virus isolation, and subsequent subtyping (7). CSF specimens were subjected to virus isolation using MDCK cells, and reverse transcription–PCR to detect influenza virus RNA by using H1/H3 subtype-specific primers. Herpes simplex virus, herpes zoster virus, and enterovirus DNA/RNA was detected using PCRs (Technical Appendix [PDF - 78 KB - 5 pages]).
CSF and plasma samples collected on the same day were analyzed simultaneously for the concentrations of 11 cytokines/chemokines by bead-based multiplex flow cytometry. Their assay methods and plasma reference ranges (established from >100 healthy persons) have been described (Technical Appendix [PDF - 78 KB - 5 pages]) (7). In CSF, in patients without central nervous system (CNS) disease/infection, cytokines/chemokines are either undetectable (e.g., interleukin-6 [IL-6], CXCL8/IL-8, CXCL10/IP-10, CXCL9/MIG) or present at low levels (e.g., CCL2/MCP-1) (8–10).
Concentrations of oseltamivir phosphate (OP) and its biologically active metabolite oseltamivir carboxylate (OC) were measured in CSF and plasma taken simultaneously from 1 patient who received concurrent treatment, using tandem mass spectrometry (11). The assay methods have been described (Technical Appendix [PDF - 78 KB - 5 pages]).
The clinical and virologic findings are summarized in Table 1. All case-patients were elderly (72–86 years of age), but none were known to have neuropsychiatric illness, dementia, or to be taking psychotropic medication. None had received updated influenza vaccination (6). Confusion and altered consciousness developed in patients 1 and 2 one to 2 days after the onset of fever and cough. These patients had no meningismus, focal neurologic deficit, hypotension, respiratory distress, or metabolic disturbances. Brain computed tomography (CT) scans showed no acute cerebral lesion. CSF analyses showed no bacterial or viral pathogen or pleocytosis. Oseltamivir was given to patient 2 only when influenza A was later confirmed by nasopharnygeal aspirate/IFA; patient 1 did not receive antiviral treatment. Both patients recovered in the next 2 days. Patient 3 had fever, severe chronic obstructive pulmonary disease exacerbation requiring noninvasive ventilatory support, complicated by acute coronary syndrome. He was given oseltamivir, 75 mg 2×/day, after influenza A infection was confirmed. Agitation and confusion developed in the patient on day 3–4 of illness (onset after the third dose of oseltamivir), despite resolution of the patient’s respiratory failure. These symptoms were followed by involuntary, tremulous movements involving all 4 limbs, while at rest and during movement. Brain CT scan was normal. Electroencephalogram showed generalized slowing. Oseltamivir was stopped after the ninth dose, but tremor persisted. CSF analyses showed no pathogen or pleocytosis. The patient’s symptoms resolved in the next 3–4 days without sequelae.
Despite apparently normal CSF findings, high concentrations of cytokines/chemokines were detected in the CSF and plasma specimens of all patients (Table 2). Plasma concentrations of IL-6, CXCL8/IL-8, CXCL10/IP-10, CCL2/MCP-1, and CXCL9/MIG were elevated at median values of 2.0, 2.8, 11.9, 3.7, and 2.1× the upper limits of their respective reference ranges (comparable to or higher than that observed in other hospitalized influenza patients) (Table 2) (7). Other cytokines were not elevated (4,7). In their CSF, IL-6, CXCL8/IL-8, CXCL10/IP-10, and CCL2/MCP-1 were consistently detected, and were elevated at median values of 2.6, 15.0, 3.4, and 20.0 × the upper limits of their respective plasma reference ranges. The CSF/plasma concentration ratios of CXCL8/IL-8 and CCL2/MCP-1 were >3 (median CSF/plasma ratio 5.4 and 8.0, respectively).
Simultaneous CSF and plasma OC and OP concentrations were determined for patient 3, as symptoms progressed at 18 h after oseltamivir. The concentrations (mean ± SD) of OC in duplicate CSF and plasma samples were 18.3 ± 0.9 ng/mL and 143.8 ± 3.3 ng/mL, respectively; the CSF/plasma concentration ratio was 12%–13%. The OP plasma concentration was 1.05 ± 0.03 ng/mL; it was not detectable in the CSF.
We report 3 adults with acute encephalopathy (altered consciousness, confusion) associated with influenza. High CSF and blood cytokine/chemokine (CXCL8/IL-8, CCL2/MCP-1, IL-6, CXCL10/IP-10) levels were detected. No evidence of direct viral neuroinvasion was found. All patients recovered rapidly without sequelae (1,6).
Our findings agree with studies of influenza-associated encephalopathy in children. Influenza virus is rarely detected in the CSF, and pleocytosis is often absent (1,2,4–6). High levels of cytokines (e.g., IL-6, soluble tumor necrosis factor receptor 1) can be consistently found in CSF/blood specimens, correlating with disease severity and outcomes (hyperactivated cytokine response is absent in febrile seizure associated with influenza) (2–4,8). We found a broader range of cytokines/chemokines being activated (7); for certain cytokines (CXCL8/IL-8, CCL2/MCP-1), the CSF concentrations were 3× those in plasma. IL-6, CXCL8/IL-8, CCL2/MCP-1 and CXCL10/IP-10 have been shown to play pathogenic roles in CNS viral infections, cerebral injury, and acute brain syndrome in susceptible patients (7,9,12). The high CSF/plasma ratios suggest that for some cytokines, activation within the CNS might have occurred along with respiratory-tract and systemic productions (cytokines are not detected in CSF normally; (Table 2) (4,7–10,12). Resident macrophages/monocytes, astrocytes, microglial and endothelial cells in the CNS are shown to release cytokines/chemokines when stimulated by viral/influenza infection; activation mechanisms without involving overt CNS invasion have been suggested (1,4,9,12–14). Cytokines may cause direct neurotoxic effects, cerebral metabolism changes, or breakdown of the blood-brain-barrier (endothelial injury) to produce symptoms (1–4,8,12–14). Whether early viral suppression by antivirals can lead to attenuation of these cytokine responses and better outcomes warrants further study (7).
We measured oseltamivir concentrations because of the concerns over its neuropsychiatric side-effects in children and adolescents. However, only the active metabolite (OC) was detected in the CSF of patient 3; the CSF/plasma concentration ratio was 12%–13% (18.3/143.8 ng/mL) at 18-hours postdose. This degree of CSF penetration is similar to that observed among healthy patients, with a Cmax CSF/plasma concentration ratio of 3.5% (at ≈8 hours), and a ratio of ≈10% at 18 hours (concentration-time profiles for plasma/CSF differ). Assuming a similar ratio, the CSF OP concentration would have fallen below the assay’s detection limit (0.25 ng/mL) by 18 hours (11,15). The low CSF drug-penetration, together with high cytokines in CSF and symptom progression despite drug withdrawal suggest that the manifestations of patient 3 may have been disease-related. Symptoms developed in patients 1 and 2 without antiviral exposure. Further investigations on the CNS effects of oseltamivir in the clinical setting are needed..
Our study is limited by the small patient number and the lack of feasibility in obtaining CSF for study/comparison in influenza patients without neurologic symptoms. Further studies on the clinical spectrum of influenza encephalopathy and encephalitis in adults (1,6) and their pathogenesis are indicated. In conclusion, acute encephalopathy may occur in adults with influenza. Exuberant cytokine/chemokine response may play an important role in its pathogenesis.
Dr Lee is an associate professor in infectious diseases at The Chinese University of Hong Kong. His primary research interest is severe emerging infections, including severe acute respiratory syndrome and influenza.
We thank Rity Wong for clerical assistance.
This study was supported by a research fund from the Department of Medicine and Therapeutics, The Chinese University of Hong Kong.
- Studahl M. Influenza virus and CNS manifestations. J Clin Virol. 2003;28:225–32.
- Morishima T, Togashi T, Yokota S, Okuno Y, Miyazaki C, Tashiro M, ; Collaborative Study Group on Influenza-Associated Encephalopathy in Japan. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002;35:512–7.
- Togashi T, Matsuzono Y, Narita M, Morishima T. Influenza-associated acute encephalopathy in Japanese children in 1994–2002. Virus Res. 2004;103:75–8.
- Kawada J, Kimura H, Ito Y, Hara S, Iriyama M, Yoshikawa T, Systemic cytokine responses in patients with influenza-associated encephalopathy. J Infect Dis. 2003;188:690–8.
- van Zeijl JH, Bakkers J, Wilbrink B, Melchers WJ, Mullaart RA, Galama JM. Influenza-associated encephalopathy: no evidence for neuroinvasion by influenza virus nor for reactivation of human herpesvirus 6 or 7. Clin Infect Dis. 2005;40:483–5.
- Steininger C, Popow-Kraupp T, Laferl H, Seiser A, Gödl I, Djamshidian S, Acute encephalopathy associated with influenza A virus infection. Clin Infect Dis. 2003;36:567–74.
- Lee N, Wong CK, Chan PKS, Lun SWM, Lui G, Wong B, Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A infections. Clin Infect Dis. 2007;45:723–31.
- Ichiyama T, Morishima T, Isumi H, Matsufuji H, Matsubara T, Furukawa S. Analysis of cytokine levels and NF-kappaB activation in peripheral blood mononuclear cells in influenza virus-associated encephalopathy. Cytokine. 2004;27:31–7.
- Lahrtz F, Piali L, Spanaus KS, Seebach J, Fontana A. Chemokines and chemotaxis of leukocytes in infectious meningitis. J Neuroimmunol. 1998;85:33–43.
- Sprenger H, Rösler A, Tonn P, Braune HJ, Huffmann G, Gemsa D. Chemokines in the cerebrospinal fluid of patients with meningitis. Clin Immunol Immunopathol. 1996;80:155–61.
- Lindegårdh N, Hanpithakpong W, Wattanagoon Y, Singhasivanon P, White NJ, Day NP. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;859:74–83.
- Semmler A, Hermann S, Mormann F, Weberpals M, Paxian SA, Okulla T, Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation. 2008;5:38.
- Wang G, Zhang J, Li W, Xin G, Su Y, Gao Y, Apoptosis and proinflammatory cytokine responses of primary mouse microglia and astrocytes induced by human H1N1 and avian H5N1 influenza viruses. Cell Mol Immunol. 2008;5:113–20.
- Yokota S, Imagawa T, Miyamae T, Ito S, Nakajima S, Nezu A, Hypothetical pathophysiology of acute encephalopathy and encephalitis related to influenza virus infection and hypothermia therapy. Pediatr Int. 2000;42:197–203.
- Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B, Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and caucasian volunteers. Antimicrob Agents Chemother. 2008;52:3687–93.
- Table 1. Clinical and laboratory findings in 3 patients with acute encephalopathy associated with influenza infection, Prince of Wales Hospital, Hong Kong
- Table 2. Cytokine and chemokine concentrations in CSF and plasma samples from 3 patients with acute encephalopathy associated with influenza A infection, Prince of Wales Hospital, Hong Kong
Technical AppendixCite This Article
Please use the form below to submit correspondence to the authors or contact them at the following address:
Nelson Lee, Division of Infectious Diseases, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 9/F Clinical Sciences Building, Department of Medicine and Therapeutics, Shatin, Hong Kong, People’s Republic of China
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 31, 2011
- Page last updated: March 31, 2011
- Page last reviewed: March 31, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)